Just One Blood Draw... Nasdaq Biotech Market Cap Soars by $15 Billion on Blood Cancer Test Hopes

Guardant Health Inc. (GH) closed at $90.90 on the Nasdaq on the 25th, up 8.75%. Its market capitalization stands at approximately $11.9 billion (about KRW 16 trillion), having gained roughly $1.1 billion (around KRW 1.5 trillion) in a single day. Trading volume exceeded 1.75 million shares.

In early March, the company partnered with actor and cancer advocate Patrick Dempsey to launch a campaign promoting its colorectal cancer blood test, Shield, intensifying its marketing efforts for Colorectal Cancer Awareness Month. In February, ahead of Awareness Month, Guardant Health introduced a community screening grant program to provide up to 100 free Shield tests to nonprofit and local health organizations, further expanding access to screening.

Headquartered in Palo Alto, California, Guardant Health is a precision oncology company specializing in cancer diagnostics, with its blood-based liquid biopsy test Guardant360 and its colorectal and multi-cancer early detection platform Shield as its flagship offerings. In 2025, annual revenue rose 33% year-over-year to $982 million (approximately KRW 1.3 trillion), and the Shield multi-cancer test received FDA Breakthrough Device designation, enhancing growth prospects.